Antibody

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Thursday, September 23, 2021 - 7:01pm

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.

The Worldwide Meat Substitutes Industry is Expected to Reach $4 Billion by 2027 - ResearchAndMarkets.com

Thursday, September 23, 2021 - 3:58pm

According to the publisher, the meat substitutes market is estimated to be valued at USD 1.9 billion in 2021 and is projected to reach USD 4.0 billion by 2027, recording a CAGR of 13.5%, in terms of value.

Key Points: 
  • According to the publisher, the meat substitutes market is estimated to be valued at USD 1.9 billion in 2021 and is projected to reach USD 4.0 billion by 2027, recording a CAGR of 13.5%, in terms of value.
  • The market is primarily driven by factors such as increasing health-consciousness among consumers and a rise in consumption of plant-based foods.
  • North America region accounted for the market share in the meat substitutes market owing to the rising investments and consumers' demand for vegan products in the region.
  • However, one of the restraining factors in the growth of meat substitutes market is the high production cost of meat substitute products.

Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design

Thursday, September 23, 2021 - 1:00pm

We continue to leverage and integrate cutting-edge technologies that advance our antibody discovery and optimization capabilities, and deepCDR offers a unique approach enabled by deep learning to generate large panels of fully human antibody sequences.

Key Points: 
  • We continue to leverage and integrate cutting-edge technologies that advance our antibody discovery and optimization capabilities, and deepCDR offers a unique approach enabled by deep learning to generate large panels of fully human antibody sequences.
  • Utilizing these sequences, weve built multiple fully human nave synthetic antibody libraries specifically AI Hypermutated single-chain fragment variable (scFv) library and a new coronavirus specific scFv library to add to our ever-growing Library of Libraries, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist has deep and broad expertise in designing and synthesizing very large antibody libraries as well as optimizing potential antibodies to improve their biochemical properties.
  • We then apply our deep learning algorithms to decrease the downstream validation work necessary for preclinical development.

A New Neutralizing Antibody Test Shows Your Body's Response to the COVID-19 Vaccine

Thursday, September 23, 2021 - 1:59pm

Our neutralizing antibody test correctly identifies the number of neutralizing antibodies you have with 100% specificity.

Key Points: 
  • Our neutralizing antibody test correctly identifies the number of neutralizing antibodies you have with 100% specificity.
  • Because the neutralizing antibody test is ordered directly by consumers online it is usually not covered by health insurance.
  • Epitome Risk is the only company offering a neutralizing antibody test from the comfort of your own home.
  • Vaccine makers announced that the number of COVID-blocking neutralizing antibodies goes down about six months after you got the vaccine.

 Celltrion Awarded up to $626 Million From the Department of Defense to Supply COVID-19 Point-of-Care (POC) Rapid Antigen Test Kits

Thursday, September 23, 2021 - 8:00am

Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.

Key Points: 
  • Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
  • Celltrions supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea.
  • The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
  • Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs.

ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer's, Parkinson's, and Other Neuro-Degenerative Diseases

Thursday, September 23, 2021 - 1:26am

LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.

Key Points: 
  • LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.
  • Approval of this patent further strengthens Company's IP portfolio of its SMART* Molecules technology and brings the management closer to the clinical trials.
  • ICBII's SMART molecules technology is blazing the path to non-invasively diagnosis and potentially curing brain diseases by delivering drugs to targeted sites that has not been possible so far.
  • The drugs that do cross the blood brain barrier only provide short-term symptomatic relief without altering disease progression.

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Wednesday, September 22, 2021 - 11:00pm

"We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond," said Carl Hansen, Ph.D., CEO and President of AbCellera.

Key Points: 
  • "We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond," said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
  • Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.
  • AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Wednesday, September 22, 2021 - 11:00pm

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.

Key Points: 
  • AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
  • We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
  • Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.

Tectonic Therapeutic Named an “Endpoints 11” Winner

Wednesday, September 22, 2021 - 5:00pm

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech.

Key Points: 
  • Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech.
  • Selected by Endpoints News founder and editor John Carroll, the Endpoints 11 recognizes biotech companies that are poised to develop new and impactful medicines: an outstanding team, a transformative approach/platform, and substantial capital.
  • Tectonics novel approach has the potential to unlock the full therapeutic utility of GPCRs.
  • We are honored to be recognized as one of the Endpoints 11 companies for our work in transforming the discovery of novel GPCR-targeted therapies, said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.

Global Immunoglobulins Market Outlook & Forecast Report 2021-2026 with CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A Dominating the Industry - ResearchAndMarkets.com

Wednesday, September 22, 2021 - 2:29pm

The study considers the immunoglobulins market present scenario and its market dynamics for the period 2020-2026.

Key Points: 
  • The study considers the immunoglobulins market present scenario and its market dynamics for the period 2020-2026.
  • The market is led by primary immunodeficiency, which acquired 26.05% of the global immunoglobulins market in 2020.
  • The key players in the immunoglobulins industry are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG.
  • The global immunoglobulins industry is dominated by mainly three vendors, CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A.